Retatrutide
Clinical TrialsRetatrutide (LY3437943)
- Category
- Weight Loss & Metabolism
- Aliases
- LY3437943, Triple-G
- Administration
- Subcutaneous injection (once weekly)
Documented side effects
Tier 1 · Peer-reviewed / regulatoryNausea
A common digestive side effect, often most noticeable when starting or increasing the dose.
Vomiting
A gastrointestinal side effect that can accompany nausea, particularly early in treatment.
Diarrhea
A gastrointestinal side effect commonly reported with this class of compound.
Long-term safety still under study
This compound is newer to human research, and its long-term safety profile is still being established.